Janssen Biotech, Inc. announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults living with moderate to...
Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has approved Tremfya (guselkumab injection) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.
The UK NICE has recommended the use of Tremfya (guselkumab), from Janssen, as a cost-effective treatment for plaque psoriasis for...
If approved, guselkumab will be the first selective IL-23 p19 subunit inhibitor for people in the European Union with active psoriatic arthritis.
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA seeking approval of Tremfya (guselkumab) for treatment of adults with moderately to severely active ulcerative colitis (UC)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new long-term data from the open-label period of the Phase III...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the ECLIPSE study demonstrating that Tremfya (guselkumab) was superior...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced comprehensive efficacy and safety data from the DISCOVER–2 trial of Tremfya (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.